ClinicalTrials.gg
DrugBiological

Agalsidase alfa clinical trials

Also written Replagal and DRX005B.

studies test it
18
open now
1
in phase 3
5
first study started
2001

How each study uses agalsidase alfa is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the agalsidase alfa studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
Not in FDA's approval records
European Union
3 Aug 2001 · Replagal · EMEA/H/C/000369 (EMA)

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

agalsidase alfa
7
Replagal (agalsidase alfa)
2

Brand

Replagal
14

Development codes

DRX005B
2
TAK-675
1
SHP675
1

Other names

recombinant alpha-galactosidase A
1

Studies by the year they started

18 studies that test it; most in 2003 (3)

Studies that test agalsidase alfa, by start year
YearStudies
20011
20021
20033
20043
20051
20081
20101
20113
20171
20211
20222

By phase

A phase 1/2 study counts in both.

Phase 1
1
Phase 2
7
Phase 3
5
Phase 4
4
No phase
1

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 9 · Other 9

Shire (8) · National Institute of Neurological Disorders and Stroke (NINDS) (5) · University Hospital, Rouen (1) · Takeda (1) · Baylor Research Institute (1) · Rigshospitalet, Denmark (1) · Assistance Publique - Hôpitaux de Paris (1)

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Tested against it · 1 phase 3 study under way

Agalsidase alfa is the comparator. A study of two new drugs counts under both.

Reaching primary completion within a year · 1

Studies that test agalsidase alfa.

Studies

Open first, then newest update. How each study uses agalsidase alfa is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 18

Given beside what is tested · 1 — agalsidase alfa is usual care or a partner of the new treatment
As the comparator · 2 — what is tested is compared with agalsidase alfa

Codes

What other systems call agalsidase alfa · ClinicalTrials.gg INT000931

  • MeSH (NLM) C000627036agalsidase alfaConfirmed ClinicalTrials.gov, NLM
  • UNII (FDA) 2HLC17MX9GAGALSIDASE ALFAConfirmed FDA, NLM
  • RxNorm 259351One source FDA
  • NCI Thesaurus C74209Agalsidase AlfaOne source FDA

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.